Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1642 1652 1654 1671
This examiner grants 57% of resolved cases
Sean E. Aeder is a highly experienced examiner in Tech Center 1600, having resolved 1431 cases. His allowance rate of 57.0% indicates a moderate level of difficulty for applicants, with just over half of the 1431 cases reaching a grant. This 57.0% rate is based on a very large sample size, making it a reliable indicator of the examiner's general tendencies. Practitioners should prepare for a thorough examination process given this volume of work.
The interview lift is 19.9%, which suggests that interviews are a beneficial strategy for improving allowance odds. This 19.9% lift indicates that direct communication with the examiner can help resolve issues more effectively than written responses alone. The median days to allowance is 1124, providing a clear timeframe for successful prosecution. This 1124-day median, combined with the 19.9% lift, suggests that while the process may take time, active engagement can significantly enhance the 57.0% chance of success.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18746198 | DETECTING NEOPLASM | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 18359569 | LDL RECEPTOR-DIRECTED BISPECIFIC BINDING AGENT-LIGAND FUSIONS FOR THE DEGRADATION OF TARGET PROTEINS | Non-Final OA | The Regents of the University of California |
| 18030223 | ENHANCEMENT OF ANTI-TUMOR PHAGOCYTOSIS | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 18042441 | METHODS OF TREATING CANCER BY ADMINISTERING A PD-1 INHIBITOR | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18010580 | BIOMARKER BASED PATIENT SELECTION FOR PROTEASOME INHIBITOR TREATMENT | Non-Final OA | University of Utah Research Foundation |
| 18193917 | METHODS FOR THE DETECTION AND TREATMENT OF LUNG CANCER | Non-Final OA | Board of Regents, The University of Texas System |
| 18528327 | NATURAL KILLER T CELL LIGAND LOADED EXTRACELLULAR NANOVESICLE AND AUTOLOGOUS ANTI-CANCER VACCINE FOR HEMATOLOGIC MALIGNANCIES COMPRISING THE SAME | Non-Final OA | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION |
| 18683858 | OFATUMUMAB FOR TREATING PEDIATRIC MS | Non-Final OA | NOVARTIS AG |
| 17753632 | TREATMENT OF RMS BY SWITCHING THERAPY | Non-Final OA | Novartis AG |
| 18018807 | PHARMACEUTICAL COMPOSITION COMPRISING CELL EXPRESSING CHIMERIC RECEPTOR | Final Rejection | Yamaguchi University |
| 17779716 | COMPOSITIONS AND METHODS FOR TREATING DISEASES AND CONDITIONS BY DEPLETION OF MITOCHONDRIAL OR GENOMIC DNA FROM CIRCULATION | Final Rejection | Cedars-Sinai Medical Center |
| 18286721 | COMPOSITIONS AND METHODS FOR TREATING CHRONIC ACTIVE WHITE MATTER LESIONS / RADIOLOGICALLY ISOLATED SYNDROME | Non-Final OA | BIOGEN MA INC. |
| 18122194 | METHODS OF TREATING GLIOBLASTOMA | Non-Final OA | Ramot at Tel-Aviv University Ltd. |
| 17918479 | TARGETING ABCB5 IN GLIOBLASTOMA MULTIFORME | Non-Final OA | The Brigham and Women's Hospital, Inc. |
| 17294401 | COMPOSITIONS AND METHODS FOR THE CYTOPLASMIC DELIVERY OF ANTIBODIES AND OTHER PROTEINS | Final Rejection | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18247878 | TREATMENT OF NSCLC PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES | Non-Final OA | Iovance Biotherapeutics, Inc. |
| 18563581 | IMMUNE CHECKPOINT INHIBITOR AND HDAC INHIBITOR COMBINATION THERAPY STRATEGY | Final Rejection | H. Lee Moffitt Cancer Center and Research Institute, Inc. |
| 18365369 | Method for Determining Prognosis of Cancer | Non-Final OA | Queen Mary University of London |
| 18549346 | MULTISPECIFIC BINDING AGENTS AGAINST CD40 AND CD137 IN THERAPY | Non-Final OA | BIONTECH SE |
| 18392902 | METHODS FOR DELIVERING ANTIBODIES TO THE FETAL CIRCULATION | Final Rejection | The Children's Medical Center Corporation |
| 17642935 | ATP-BASED CELL SORTING AND HYPERPROLIFERATIVE CANCER STEM CELLS | Non-Final OA | LUNELLA BIOTECH, INC. |
| 18587839 | HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS | Final Rejection | Xencor, Inc. |
| 18691267 | OPTIMIZED MULTABODY CONSTRUCTS, COMPOSITIONS, AND METHODS | Non-Final OA | Radiant Biotherapeutics Inc. |
| 18249957 | PVRL2 AND/OR PVRIG AS BIOMARKERS FOR TREATMENT | Non-Final OA | COMPUGEN LTD. |
| 18024471 | ANTI-CD47 MONOCLONAL ANTIBODY AND USE THEREOF | Final Rejection | Akeso Pharmaceuticals, Inc. |
| 18256191 | DIAGNOSTIC METHOD FOR MULTIPLE SCLEROSIS | Non-Final OA | Belgian Volition SRL (BE/BE) |
| 18252904 | NEAR INFRARED-II PROBES AS HIGH AFFINITY TARGETING IMAGING AGENTS AND USES THEREOF | Non-Final OA | On Target Laboratories, LLC |
| 17916068 | REDUCED CALORIC INTAKE AND IMMUNOTHERAPY FOR THE TREATMENT OF CANCER | Non-Final OA | IFOM FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE |
| 17790278 | METHOD FOR TREATING GASTRIC CANCER BY BLOCKING CCL28 CHEMOTACTIC PATHWAY | Final Rejection | CHANGEN THERAPEUTICS (SHANGHAI) CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy